Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11502520 | 0.70 | MAPT (0.41) | MAPT | |
| SCHEMBL4265406 | 0.68 | MAPT (0.32) | MAPT | |
| SCHEMBL4268787 | 0.68 | MAPT (0.35) | MAPT | |
| SCHEMBL277115 | 0.64 | GSTP1 (0.37) | MAPT | |
| SCHEMBL4273597 | 0.61 | MAPT (0.32) | MAPT | |
| SCHEMBL4269254 | 0.61 | MAPT (0.35) | MAPT | |
| SCHEMBL4269969 | 0.61 | MAPT (0.32) | MAPT | |
| SCHEMBL5791186 | 0.60 | BRD4 (0.41) | MAPT | |
| SCHEMBL8309049 | 0.59 | BRD4 (0.37) | MAPT | |
| SCHEMBL1943625 | 0.59 | BACE1 (0.39) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605183-B2 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO | 2009-10-20 | — | — | US | disclosed |
| US-20080200558-A1 | Inhibitory or blocking agents of molecular generating and/or/ inducing functions | KOYAMA SHOZO | 2008-08-21 | — | — | US | disclosed |
| US-20070066654-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO | 2007-03-22 | — | — | US | disclosed |
| EP-0780122-B1 | DEPRESSANT OF FUNCTIONS DEVELOPED BY MOLECULE | KOYAMA SHOZO (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20040224926-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6710090-B2 | A CYCLOHEX-1-EN-2-ONE COMPOUND | KOYAMA SHOZO (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20020165206-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO (JP) | 2002-11-07 | — | — | US | disclosed |
| US-6346551-B1 | ANTIBACTERIAL, ANTIFUNGAL, ANTIVIRAL, BACTERICIDAL AND/OR STERILIZATION AGENTS, ANTICANCER DRUGS, BLOOD COAGULATION AND FIBRINOLYSIS INHIBITORS AND/OR BLOCKING AGENTS, INHIBITORY AND/OR BLOCKING AGENTS OF ANTIGEN-ANTIBODY REACTIONS | KOYAMA SHOZO (JP) | 2002-02-12 | — | — | US | disclosed |
| EP-0780122-A1 | DEPRESSANT OF FUNCTIONS DEVELOPED BY MOLECULE | Koyama, Shozo (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066654-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD47, SERPINB6, CD74 | MAPT 4875/4885 |
| US-20020165206-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD69, TFPI, SERPINE1 | MAPT 2607/4885 |
| US-20040224926-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD47, MCL1, CD74 | MAPT 4860/4885 |
| US-20080200558-A1 | Inhibitory or blocking agents of molecular generating and/or/ inducing functions | CD47, MCL1, BAK1 | MAPT 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.